Alvine Pharmaceuticals Closes a $21 Million Series A Financing

Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Closes a $21 Million Series A Financing

September 12, 2006

PALO ALTO, Calif. — September 12, 2006 — Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on developing pharmaceutical products for the treatment of celiac sprue, today announced the closing of a $21 million Series A financing. Sofinnova Ventures led the investment round with strong support from Prospect Venture Partners and InterWest Partners. Cargill Ventures and Flagship Ventures also participated in the financing.

"This financing brings together a premier group of investors committed to advancing the company’s lead product candidate ALV001 into human clinical and safety trials," said Stanford Professor Chaitan Khosla, Ph.D., who co-founded the company. “Celiac sprue is a serious yet common immune disease that is triggered by gluten, a component of cereal grains found in most foods sold in the U.S. While under-diagnosed, as many as one in one hundred individuals suffer from celiac sprue, yet there is no drug therapy available. Alvine’s mission is to provide innovative drug therapies for this disease and to change the lives of its many patients,” he continued.

“Sofinnova has known Chaitan since the early 90’s when we worked together on behalf of Kosan Biosciences. We’re thrilled to be working with him again on his current venture,” commented Sofinnova Ventures General Partner Nicola Campbell, Ph.D. “Alvine’s lead products will be beneficial to the celiac market for the treatment of a neglected patient population. ALV001 has proven to be uniquely safe for patients with celiac sprue, an actuality that the management team and investors alike are proud of."

Joining Khosla in this venture are Alvine co-founders Blair Stewart, President and Kevin Kaster, Vice President of Corporate Development.

Alvine’s platform is based on over six years of research, and an extensive intellectual property portfolio licensed from Stanford University and acquired from the Celiac Sprue Research Foundation.
The Alvine Board of Directors consists of: Nicola Campbell, Ph.D., General Partner, Sofinnova Ventures; Ilan Zipkin, Ph.D., Partner, Prospect Venture Partners; Nina Kjellson, Partner, InterWest Partners; and Chaitan Khosla, Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering; Professor of Chemical Engineering, Chemistry, and Biochemistry, by courtesy, of Stanford University.

About Alvine

Alvine Pharmaceuticals, Inc., is a Palo Alto-based biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of Celiac sprue. Alvine’s lead molecule, ALV001, is a protease designed to be consumed with food to detoxify the gluten that triggers the autoimmune response in celiac patients. Celiac sprue is believed to affect as many as two million people in the United States alone, many of whom have suffered the symptoms of the disease but have not yet been diagnosed.

About Sofinnova Ventures

For information on Sofinnova Ventures, visit www.sofinnova.com.

About Prospect Venture Partners

For information on Prospect Venture Partners, visit www.prospectventures.com.

About InterWest Partners

For information on InterWest Partners, visit www.interwest.com.

About Cargill Ventures

For information on Cargill Ventures, visit www.cargillventures.com.

About Flagship Ventures

For information on Flagship Ventures, visit www.flagshipventures.com.

Contact:

Karen Roberson (for Alvine)
(415) 228-3395
karen@sofinnova.com